People: Anika Therapeutics Inc (ANIK.O)

ANIK.O on Nasdaq

6.49USD
9 Feb 2010
Price Change (% chg)

$0.09 (+1.41%)
Prev Close
$6.49
Open
--
Day's High
$6.53
Day's Low
$6.42
Volume
11,321
Avg. Vol
30,846
52-wk High
$9.25
52-wk Low
$3.00

view people for:

Summary

Name Age Since Current Position
Sherwood, Charles 62 2002 President, Chief Executive Officer, Director
Quinlan, Kevin 59 2005 Chief Financial Officer, Treasurer, Secretary
Luppino, Frank 38 2009 Chief Operating Officer
Wilhoite, Randall 43 2007 Vice President - Operations
Mrachek, William 65 2008 Vice President - Human Resources
Kulinets, Irina 54 2007 Vice President - Regulatory and Clinical Affairs
Carter, Andrew 53 2008 Chief Technology Officer
Bower, Joseph 70 2005 Lead Director
Davidson, Eugene 78 1993 Director
Wheeler, Steven 62 1993 Director
Land, Raymond 64 2006 Director
Moran, John 56 2006 Director
» Insider Trading

Biographies

Name Description
Sherwood, Charles Dr. Sherwood was appointed Chief Executive Officer of Anika Therapeutics, Inc. in March 2002. Dr. Sherwood has served as President since June 2001. Dr. Sherwood previously served as Anika Therapeutics' Chief Operating Officer beginning in June 2001, Vice President of Research and Development beginning in April 2000 and Vice President of Process Development and Engineering beginning in April 1998. Dr. Sherwood served as a consultant to Anika Therapeutics from January 1998 to April 1998. From 1995 to 1997, Dr. Sherwood was Senior Director of Medical Device Research and Development for Chiron Vision. In April 1995, Chiron Vision acquired IOLAB Corporation, a division of Johnson & Johnson where Dr. Sherwood had been Executive Director of Research and Development from 1993 to 1995, Director of Materials Characterization from 1989 to 1993 and Manager/Section Head from 1982 to 1989. Dr. Sherwood was also a part-time faculty member in the Department of Chemistry at the California State Polytechnic University, Pomona, California from 1984 to 1987. Dr. Sherwood received a B.S. in Chemical Engineering from Cornell University, and an M.S. and Ph.D. in Polymer Science and Engineering from the University of Massachusetts, Amherst. Dr. Sherwood also received a Certificate in Management from Claremont Graduate School.
Quinlan, Kevin Mr. Quinlan was appointed Chief Financial Officer, Treasurer and Secretary of Anika Therapeutics, Inc. in July 2005. Previously, Mr. Quinlan was President of BBI Diagnostics, a division of SeraCare, which was acquired in 2004 from Boston Biomedica, Inc ("BBI"). From 1999 to 2004, Mr. Quinlan served as President and Chief Operating Officer of BBI, then a publicly traded manufacturer of quality control products used to monitor infectious disease testing, and had operational and financial responsibility for BBI's five business units. Mr. Quinlan previously served as Chief Financial Officer of BBI from 1993 to 2003. As Chief Financial Officer, he was responsible for finance, IT, treasury, human resources and investor relations. From 1990 to 1993, Mr. Quinlan was Chief Financial Officer of Parctec, Inc. (a subsidiary of Kleinwort Benson Group). From 1981 to 1990, Mr. Quinlan was Vice President, Assistant Treasurer and Corporate Controller of American Finance Group. From 1975 to 1981, Mr. Quinlan was an auditor/senior auditor/audit supervisor at Coopers & Lybrand. Mr. Quinlan is a Certified Public Accountant and has a BS degree from the University of New Hampshire and a MS degree from Northeastern University.
Luppino, Frank Mr. Frank Luppino has been appointed as Chief Operating Officer of Anika Therapeutics, Inc effective May 26, 2009. He has served as Vice President of Operations of Anika Therapeutics in June 2003. Mr. Luppino was previously Executive Director of Operations at Anika Therapeutics. Prior to joining Anika Therapeutics in 1998, Mr. Luppino was Regional Manager for AAC Consulting Group, a firm serving the pharmaceutical and medical device industries. From 1992 to 1998, he was Regional Manager for Raytheon Engineers and Constructors, where he executed design, start-up and validation projects for clients in the pharmaceutical and biotechnology industries. Prior to that, Mr. Luppino was a Project Engineer with Black and Veatch, an architectural and engineering design firm. Mr. Luppino holds a bachelor’s degree in chemical engineering from Lehigh University.
Wilhoite, Randall Mr. Wilhoite joined Anika Therapeutics, Inc. in January 2006 as Director of Planning and Logistics and in September 2007 was promoted to Vice President of Operations. Prior to joining Anika, Mr. Wilhoite was a supply chain manager for Oscient Pharmaceuticals, a biopharmaceutical company that develops therapeutics to address unmet medical needs. From 1988 to 2004, he held various management positions at Abbott Laboratories with increasing responsibilities in operations, planning and distribution. Mr. Wilhoite holds a bachelor's degree in chemistry from the University of Indiana.
Mrachek, William Mr. Mrachek joined Anika Therapeutics, Inc. in 2001 and in 2008 was promoted to Vice President of Human Resources after serving as the Executive Director of Human Resources since 2003. Previously, Mr. Mrachek served as the Vice President of Human Resources for iQ NetSolutions, a start-up engaged in the proprietary Enterprise telephony solutions converging both voice and data. From 1994 to 2000, Mr. Mrachek was Director of Human Resources for Programart Corp in Cambridge, MA, a private software company developing application performance management products for the mainframe market. Previously, Mr. Mrachek served as Vice President of Human Resources for SofTech, Inc., a public company located in Waltham, MA, engaged in selling software development and engineering services primarily for the Federal government as well as the product reselling of computers, network equipment, and packaged software. Mr. Mrachek holds a BA degree from Colorado College, a MBA from the University of Denver, and a JD from the University of Colorado School of Law. He serves on the Board of Directors for the Faulkner Hospital in Boston.
Kulinets, Irina Ms. Kulinets joined Anika Therapeutics, Inc. in December 2007 as Vice President of Regulatory and Clinical Affairs. Prior to joining Anika, Mrs. Kulinets served as Senior Director of Regulatory Affairs at BioSphere Medical in Rockland, MA. She has 17 years of experience in the medical device industry with large and small manufacturers including Boston Scientific, Johnson & Johnson/DePuy, and OmniGuide where she served in various regulatory affairs, clinical affairs, and quality assurance technical, management and senior management roles. From 2001 to 2004, Ms. Kulinets served as a Medical Regulatory Reviewer and Lead Medical Auditor for Notified Body, TUV America. In addition, she is certified by the Food and Drug Administration as a Third Party 510K reviewer. She holds MS and BS degrees in Mechanical Engineering from Belarus Polytechnic Academy and an MS degree in Quality Assurance from California State University, Dominguez Hills. She is RAPS certified RAC, ASQ certified Six Sigma Black Belt, and ASQ Certified Quality Engineer.
Carter, Andrew Dr. Carter joined Anika Therapeutics, Inc. in January 2008 as Chief Technology Officer. Prior to joining Anika, Dr. Carter was Vice President Research, Development and General Manager at Spine Wave, Inc., a Shelton, CT privately held company focused on developing innovative medical devices for the treatment of spinal disorders. Prior to joining Spine Wave, Inc., he held a variety of positions with increasing responsibilities with Smith & Nephew in the United Kingdom, and with S&N Endoscopy in Massachusetts. Dr. Carter's research and product development responsibilities within Smith & Nephew included materials research, consumer products, wound management, orthopedics, arthroscopy and tissue engineering. Dr. Carter holds a B.S. degree and a Ph.D. in Polymer Science and Technology from Queen Mary College, the University of London.
Bower, Joseph Dr. Bower joined the Board of Directors of Anika Therapeutics, Inc. in February 1993 and has served as Lead Director since April 2005. He has held various positions at the Harvard Business School since 1963, where he was named Professor of Business Administration in 1972 and Donald Kirk David Professor of Business Administration in 1986. He has served as Chairman of the Doctoral Programs, Director of Research, Senior Associate Dean for External Relations, Chair of the General Management Area and is currently Chair of the General Manager Program. Dr. Bower received an A.B. from Harvard University and an M.B.A. and a D.B.A. from the Harvard Business School. He is a director of Brown Shoe Company, Inc., New America High Income Fund, Sonesta International Hotels Corporation, and Loews Corporation.
Davidson, Eugene Dr. Davidson joined the Board of Directors of Anika Therapeutics, Inc. in February 1993. Dr. Davidson is currently an Adjunct Professor of Biological Sciences at the Florida Atlantic University. He was the Chairman of the Department of Biochemistry, Cell and Molecular Biology at Georgetown University Medical School from April 1988 until June 30, 2003. Prior to this position, he was the Chairman of the Department of Biological Chemistry at the Milton S. Hershey Medical Center of the Pennsylvania State University from October 1967 to April 1988. Dr. Davidson also served as Associate Dean for Education at the Milton S. Hershey Medical Center from November 1975 to January 1987. Dr. Davidson received a B.S. in Chemistry from the University of California, Los Angeles, and a Ph.D. in Biochemistry from Columbia University.
Wheeler, Steven Mr. Wheeler joined the Board of Directors of Anika Therapeutics, Inc. in February 1993. He is currently the President of Wheeler & Co., a private investment firm. He is also currently a director of Bariston Partners, LLC, a private equity investment firm, PingTone, Inc., and The 81 Beacon Street Corporation. Between 1993 and February 1996, Mr. Wheeler was Managing Director and a director of Copley Real Estate Advisors and President, Chief Executive Officer and a director of Copley Properties, Inc., a publicly traded real estate investment trust. He was the Chairman and Chief Executive Officer of Hancock Realty Investors, which manages an equity real estate portfolio, from 1991 to February 1993. Prior to this position, he was an Executive Vice President of Bank of New England Corporation from 1990 to 1991. Mr. Wheeler received a B.S. in Engineering from the University of Virginia, an M.S. in Nuclear Engineering from the University of Michigan and an M.B.A. from the Harvard Business School.
Land, Raymond Mr. Land joined the Board of Directors of Anika Therapeutics, Inc. in January 2006. Mr. Land is currently Senior Vice President and Chief Financial Officer at Clarient, Inc., a Safeguard Scientifics, Inc. partner company. Mr. Land was previously Senior Vice President and Chief Financial Officer of Safeguard Scientifics, Inc., from 2007 to 2008. From 2006 to 2007, Mr. Land served as Executive Vice President and Chief Financial Officer of Medcenter Solutions, Inc. From 2005 until 2006, Mr. Land served as Senior Vice President and Chief Financial Officer of Orchid Cellmark Inc. From 1997 until 2005, Mr. Land served as Chief Financial Officer of NASDAQ-traded Genecor International, Inc., a diversified biotechnology company focusing on bioproducts and healthcare. From 1991 to 1996, he served as Senior Vice President and Chief Financial Officer for publicly traded West Pharmaceutical Services, Inc. Previously, Mr. Land was with Campbell Soup Company, Inc., where for nine years he held increasingly senior financial positions and also served as General Manager of a frozen food division. Prior to joining Campbell Soup, Mr. Land worked for Coopers and Lybrand for nine years. Mr. Land is a Certified Public Accountant and has a degree in accounting and finance from Temple University.
Moran, John Mr. Moran joined the Board of Directors of Anika Therapeutics, Inc. in December 2006. From 1990 to 1997, Mr. Moran served as the First President of Synthes Spine, a division of Synthes (USA), the major skeletal fixation company in the world. Synthes Spine designs, manufactures and distributes implants and instruments for spinal disorders. Since leaving Synthes in 1997, Mr. Moran has been a private investor in a number of companies, mostly in the medical devices field. Mr. Moran also serves as a director of Power Medical Interventions Inc., Christini Technologies, Paradigm Spine LLC, Ranier Technologies, and is Chairman of the Board at Core Essence Orthopaedics. Mr. Moran is a graduate of the University of Notre Dame and holds an M.B.A. from Harvard Business School.

Basic Compensation

Name Fiscal Year Total
Sherwood, Charles 1,039,210
Quinlan, Kevin 537,872
Luppino, Frank 273,995
Wilhoite, Randall 217,772
Mrachek, William 373,055
Kulinets, Irina 348,098
Carter, Andrew 492,012
Bower, Joseph --
Davidson, Eugene --
Wheeler, Steven --
Land, Raymond --
Moran, John --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Sherwood, Charles 685,000 4,844,239
Quinlan, Kevin 75,000 33,750
Luppino, Frank 271,750 1,530,689
Wilhoite, Randall 3,125 31,250
Mrachek, William 0 0
Kulinets, Irina 0 0
Carter, Andrew 0 0
Bower, Joseph 0 0
Davidson, Eugene 0 0
Wheeler, Steven 0 0
Land, Raymond 0 0
Moran, John 0 0

Insider Trading

Name Shares Traded Price
BOWER JOSEPH L 4,716 $0.00
LAND RAYMOND J 4,716 $0.00
WHEELER STEVEN E 4,716 $0.00
DAVIDSON EUGENE A 4,716 $0.00
MORAN JOHN C 4,716 $0.00
SHERWOOD CHARLES H 25,000 $6.94
MRACHEK WILLIAM 4,254 $0.00
SHERWOOD CHARLES H 18,780 $0.00
QUINLAN KEVIN W 6,744 $0.00
LAND RAYMOND J 2,850 $0.00
LAND RAYMOND J 7,500 $0.00
BOWER JOSEPH L 7,500 $0.00
DAVIDSON EUGENE A 7,500 $0.00
MORAN JOHN C 7,500 $0.00
WHEELER STEVEN E 7,500 $0.00
BOWER JOSEPH L 2,850 $0.00
DAVIDSON EUGENE A 2,850 $0.00
MORAN JOHN C 2,850 $0.00
WHEELER STEVEN E 2,850 $0.00
QUINLAN KEVIN W 1,000 $5.20
QUINLAN KEVIN W 1,000 $5.34
BOWER JOSEPH L 13,500 $0.91
BOWER JOSEPH L 3,000 $5.19
BOWER JOSEPH L 12,500 $0.99
WHEELER STEVEN E 13,500 $0.91
» Full list on Insider Trading
view people for: